RESEARCH & PUBLICATIONS
Selected work, explained briefly—with the original evidence one click away.
EMIRATES CARDIAC SOCIETY · APRIL 14, 2026
In “Advances in imaging for ATTR-CM,” Dr. Smiley’s presentation focuses on the role of PET in diagnosing transthyretin cardiac amyloidosis.
Professional education · Full event recording, including other speakers and discussion. Hosted by the Emirates Cardiac Society; the event lists AstraZeneca as sponsor.
RECENT PUBLICATIONS / 2026
EDUCATION & ADVOCACY · MAY 2026
In a coauthored review, Dr. Smiley and Neasa Starr reflect on specialist cardiac-amyloidosis fellowships: the skills gained, the value of mentorship and collaboration, and keeping patients at the center of service development.
Journal of Cardiac Failure · 32(5):935–938
Coauthor · Review article
CLINICAL RESEARCH · FEBRUARY 2026
Dr. Smiley contributed to a retrospective study of 419 patients examining atrial fibrillation and flutter in transthyretin cardiac amyloidosis, including factors associated with their presence and development over time.
The study also examined associations with tafamidis treatment. Its observational findings do not establish cause and effect.
JACC: Advances · 5(2):102470
Coauthor · Retrospective cohort study
FEATURED RESEARCH / 2025
Dr. Smiley is first-listed author of a study in JACC: Cardiovascular Imaging examining earlier detection of transthyretin cardiac amyloidosis with an investigational PET/CT tracer.
The study compared imaging findings in people with ATTR disease and variant carriers.
Eleven participants with grade 0 or 1 pyrophosphate scans showed cardiac uptake with the investigational tracer.
The findings suggest potential for detecting deposits missed by the comparison scan. They do not establish improved patient outcomes or universal test superiority.
Her contribution is visible in peer-reviewed research addressing a diagnostic challenge—not simply in a list of interests. The full paper provides the methods, limitations and collaborative authorship.
2025;18(7):799–811 · DOI 10.1016/j.jcmg.2025.01.018. Research overview, not a claim of test availability or regulatory approval.
View the 2025 study on PubMedSELECTED PUBLICATION / 2023
Dr. Smiley is the first-listed author of a 2023 paper describing hereditary cardiac amyloidosis detected using an investigational PET imaging approach, despite other imaging not identifying it.
This is a publication overview, not a recommendation for a test or a statement about its clinical availability. A single report should not be read as proof that one test is always better than another.
Publication records preserve the study’s original authorship, methods and limitations. We link to those records so you can explore the evidence beyond this introduction.
Explore Dr. Smiley’s training